FDA: Studies show no extra neuropsychiatric hospitalisation risk with Pfizer’s Chantix

The FDA announce Monday that following an evaluation of two agency-sponsored epidemiological studies, it has concluded that there is no difference in risk of neuropsychiatric hospitalisations between Pfizer’s Chantix (varenicline) and nicotine-replacement patches. However, the regulator noted that the studies "do not rule out an increased risk of other neuropsychiatric events with Chantix."

To read more Top Story articles, click here.